Literature DB >> 6696320

Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone.

W L Eschenbacher, H A Boushey, D Sheppard.   

Abstract

To determine whether cough and bronchoconstriction result from alterations in the osmolarity or alterations in the ion concentration of inhaled aerosols and to determine if the specific ions in the aerosol are important, we had 9 subjects with mild asthma inhale various solutions while we recorded cough and measured specific airway resistance. To evaluate the effects of altering osmolarity and ion concentration separately, we administered aerosols of hypo-osmolar distilled water (0 mosm), iso-osmolar sodium chloride (308 mosm), iso-osmolar dextrose in water (308 mosm), hyperosmolar sodium chloride (1,232 mosm), and a hyperosmolar solution of dextrose and sodium chloride (1,232 mosm). To evaluate cough without bronchoconstriction, we had the subjects inhale metaproterenol before inhaling the same aerosols. To determine whether the absence of a specific ion was important in causing cough or bronchoconstriction, we had the subjects inhale iso-osmolar solutions of sodium bromide, sodium gluconate, and lysine monohydrochloride. We found that alteration in osmolarity away from iso-osmolarity of inhaled aerosols is a stimulus for bronchoconstriction in subjects with mild asthma. Absence of ions in the presence of iso-osmolarity is not a stimulus for bronchoconstriction, but the absence of a permeant anion is a stimulus for cough. Thus, we found that the responses of cough and bronchoconstriction to inhaled aerosols can be separated.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6696320

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  47 in total

1.  Effects of methacholine induced bronchoconstriction and procaterol induced bronchodilation on cough receptor sensitivity to inhaled capsaicin and tartaric acid.

Authors:  M Fujimura; S Sakamoto; Y Kamio; T Matsuda
Journal:  Thorax       Date:  1992-06       Impact factor: 9.139

Review 2.  Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications.

Authors:  N R Labiris; M B Dolovich
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

Review 3.  Aerosolised antibacterials for the prevention and treatment of hospital-acquired pneumonia.

Authors:  G Christopher Wood; Joseph M Swanson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Relationship between the acid-induced cough response and airway responsiveness and obstruction in children with asthma.

Authors:  T Shimizu; H Mochizuki; K Tokuyama; A Morikawa
Journal:  Thorax       Date:  1996-03       Impact factor: 9.139

5.  Osmolality and pH of anti-asthmatic drug solutions.

Authors:  K N Desager; H P Van Bever; W J Stevens
Journal:  Agents Actions       Date:  1990-11

6.  Development of a High-Flow Nasal Cannula and Pharmaceutical Aerosol Combination Device.

Authors:  Benjamin M Spence; Worth Longest; Xiangyin Wei; Sneha Dhapare; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2019-03-11       Impact factor: 2.849

7.  Cough: physiology, evaluation, and treatment.

Authors:  A S Banner
Journal:  Lung       Date:  1986       Impact factor: 2.584

8.  Adverse reactions to the non-drug constituents of nebuliser solutions.

Authors:  R Beasley; P Rafferty; S T Holgate
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

9.  The effect of anticholinergic bronchodilator therapy on cough during upper respiratory tract infections.

Authors:  R Lowry; A Wood; T Higenbottam
Journal:  Br J Clin Pharmacol       Date:  1994-02       Impact factor: 4.335

10.  A Proof of Concept Study to Detect Urease Producing Bacteria in Lungs Using Aerosolized 13C-Urea.

Authors:  Hengameh H Raissy; Graham Timmins; Lea Davies; Theresa Heynekamp; Michelle Harkins; Zachary D Sharp; H William Kelly
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2016-06-01       Impact factor: 1.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.